(DCTH) Delcath Systems, Inc. Business Model Canvas Research

Delcath Systems, Inc. relies on contract manufacturers for its drug-device combination parts, sterile fill-finish, device assembly, and packaging. These partners keep quality-controlled output moving across 2 core markets, the U.S. and Europe, so supply stays steady as commercial demand changes.

• Third-party production supports sterile fill-finish.

• They handle device assembly and packaging.

• They help protect U.S. and Europe supply continuity.

Distributors and logistics providers are key for Delcath Systems, Inc. in Europe because commercialization needs regional reach, controlled logistics, and steady hospital supply. They help move HEPZATO KIT to treatment sites, keep inventory available, and reduce the need for Delcath to build a heavy in-country sales and warehousing base.

• Regional reach without local buildout
• Controlled logistics for hospital delivery
• Better inventory availability
• Lower fixed operating burden

Because Delcath Systems, Inc. sells a drug-device therapy, manufacturing and quality control are core to keeping product integrity and patient safety intact. The company’s 2025 focus should stay on release testing, quality-system compliance, and supply planning, since each batch must meet strict standards before use in patients.

• Release testing before shipment
• Regulatory quality-system controls
• Supply planning for patient access

Delcath’s regulatory and reimbursement work keeps HEPZATO KIT aligned with U.S. FDA and European rules, while it pushes payer coding and coverage so oncology centers can actually use it. This matters because the therapy serves a narrow patient group: liver-dominant metastatic uveal melanoma, where one approved U.S. option and access support can decide adoption.

• U.S. and Europe compliance
• Payer coding and coverage support
• Drives uptake in specialty oncology

Delcath Systems, Inc.’s regulatory approvals and know-how are core assets: HEPZATO KIT won FDA approval on March 15, 2023, and that experience cuts the time and risk of bringing a complex oncology therapy to market. One approved product and Delcath’s U.S. and European regulatory track record make future filings, labeling work, and market access faster and less costly.

• FDA approval de-risks commercialization
• One approved oncology therapy builds credibility
• U.S. and Europe pathway knowledge speeds filings

Delcath Systems, Inc. needs a focused commercial and medical affairs team to train physicians, support site onboarding, and drive adoption of HEPZATO KIT, which got U.S. FDA approval in 2024. In a niche interventional oncology market, this team is key for scientific exchange and for helping hospitals move from awareness to procedure use.

• Train and support treatment sites
• Educate clinicians and manage science
• Speed adoption in a small market

Delcath Systems, Inc.'s interventional oncology procedure is done in a hospital setting, so liver-tumor care stays with interventional specialists instead of full systemic oncology. That fits tertiary cancer centers with hepatic expertise, where the HEPZATO KIT is used for isolated liver disease and in-office workflow is not enough.

• Hospital-based, specialist-led care
• Fits tertiary liver cancer centers
• Targets isolated liver disease

CHEMOSAT is used in Europe for multiple liver cancer types, including metastatic disease, so Delcath Systems, Inc. can reach a wider market than in the United States. It also builds clinician familiarity across tumor types, which can support repeat use and faster adoption.

• Wider European addressable market
• Use across several liver cancer types
• More physician familiarity with CHEMOSAT

Delcath Systems, Inc. supports reimbursement support by helping hospitals and physicians with coding, payer education, and the documents needed for coverage access, which cuts adoption friction for Hepzato in 2025 care pathways.

This matters because a complex reimbursement step can slow use even after FDA approval, so Delcath’s support helps sites move from trial to routine treatment faster.

• Helps with coding and documentation
• Supports payer education
• Reduces access delays in 2025

Adopting centers need steady help with inventory, scheduling, and clinical questions, so Delcath Systems, Inc. treats each site as a long-term operating partner, not a one-time sale. That model supports repeat use and procedural consistency, which matters in a center-based therapy where follow-up support drives adoption.

• Ongoing support lowers site friction

• Repeat use depends on consistency

• Long ties fit Delcath's model

Medical conferences and peer-reviewed publications are key channels for Delcath Systems, Inc. in oncology because they put HEPZATO KIT data in front of interventional radiologists and oncologists who treat rare liver cancers. In 2025, ASCO drew about 40,000 attendees, showing why these meetings matter for reach and credibility.

• Builds awareness with specialist doctors
• Supports trust with peer-reviewed evidence
• Fits a niche, high-touch treatment platform

Delcath Systems uses its corporate website and product materials to share HEPZATO KIT details, trial updates, and investor news, which matters for a small-cap life sciences company with a limited sales force. As of its latest public filings, this channel is central for physician education and market visibility while FDA-approved product messaging stays current.

• Website: product and trial updates
• Materials: physician and investor reach
• Fit: low-cost, high-visibility channel

Oncologists and hepatobiliary specialists are the main gatekeepers for Delcath Systems, Inc. in liver-dominant cancers: they choose the treatment path, drive referrals, and shape whether a center adopts therapy. In the U.S., liver-dominant metastatic disease affects a large share of colorectal, ocular, and other cancers, so specialist buy-in is what turns clinical data into patient use.

• Drive referral flow
• Pick liver-directed care
• Decide center adoption

Academic and research hospitals are key Delcath Systems, Inc. adopters because they generate clinical evidence, run early trials, and shape treatment guidelines. In oncology, trial sites in large academic centers can speed physician awareness and help move a niche device into broader use.

• Lead trials and publish evidence
• Influence care guidelines
• Accelerate market awareness

Delcath’s sales and medical education costs are a growth-linked commercialization expense: each new center needs field support, physician training, and conference outreach. Because the therapy is specialized, these costs scale with center penetration and sit mainly in selling, general, and administrative spend in fiscal 2025.

• Field reps support new centers
• Physicians need hands-on training
• Conference spend drives awareness
• Costs rise with center growth

Delcath Systems, Inc. has to pay for regulatory compliance, legal work, finance, and corporate admin, and those costs rise because it is a public company with SEC reporting, audit, and governance duties. Headquarters and management overhead also sit in this bucket, so this line stays fixed even when sales move around.

• Regulatory, legal, finance, and admin spend
• Public-company reporting and governance costs
• Headquarters and management overhead

Once a center adopts Delcath Systems, Inc.'s therapy, repeat procedures can drive ongoing sales that are often more valuable than a one-time placement. This stream depends on patient referrals and how quickly the center builds experience, which can lift procedure volume and, in turn, recurring revenue.

• Repeat use drives recurring sales.
• Patient referrals decide volume.
• Center experience improves utilization.

Delcath Systems, Inc.’s upside sits in label expansion: a broader liver-cancer approval would move beyond today’s narrow use and open a much larger patient pool. In the U.S., about 3,000 uveal melanoma cases are diagnosed each year, while broader liver-tumor labels could also add oncology centers and support longer-term sales in Europe.

• More approved cancers
• More eligible patients
• More treatment centers
• Higher U.S. and Europe sales